ArticleFrontiers in molecular biosciences2020
Systems Biology Integration and Screening of Reliable Prognostic Markers to Create Synergies in the Control of Lung Cancer Patients.
Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- From Fibrosis to Malignancy: Mechanistic Intersections Driving Lung Cancer Progression.Cancers · 2025Review
- [Relationship between GTSE1 and Cell Cycle and Potential Regulatory Mechanisms in Lung Cancer Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Comprehensive analysis of the diagnostic and therapeutic value, immune infiltration, and drug treatment mechanisms of GTSE1 in lung adenocarcinoma.Frontiers in medicine · 2024Article
- Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.Biomedicines · 2023Review
- Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside.Frontiers in oncology · 2022Review
- Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.Journal of experimental & clinical cancer research : CR · 2021Article
- Identified GNGT1 and NMU as Combined Diagnosis Biomarker of Non-Small-Cell Lung Cancer Utilizing Bioinformatics and Logistic Regression.Disease markers · 2021Article
- Article
- NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma.Disease markers · 2021Article
- Globally ncRNAs Expression Profiling of TNBC and Screening of Functional lncRNA.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to achieve a clearer and stronger understanding of all the mechanisms involved in the occurrence as well as in the progression of lung cancer along with discovering trustworthy prognostic markers. We combined four gene expression profiles (GSE19188, GSE19804, GSE101929, and GSE18842) from the GEO database and screened the commonly differentially expressed genes (CDEGs). We performed differentially expressed group analysis on CDEGs, alteration and mutational analysis, and expression level verification of core differential genes. Systems biology discoveries in our examination are predictable with past reports. Curiously, our examination revealed that screened biomarker adjustments, for the most part, coexist in lung cancer. After screening 952 CDEGs, we found that the up-regulation of neuromedin U (NMU) and GTSE1 in the case of lung cancer is related to poor prognosis. On the other hand, FOS CDKN1C expression is associated with poor prognosis and is responsible for the down-regulation of CDKN1C and FOS. Changes in these qualities are on free pathways to lung cancer and are not usually of combined quality variety. Even though biomarkers were related to both survival occasions in our examination, it gives us another point of view while playing out the investigation of hereditary changes and clinical highlights employing information mining. Based on our results, we found potential and prospective clinical applications in GTSE1, NMU, FOS, and CDKN1C to act as prognostic markers in case of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.